Next generation of delivery platform for Prime editors based on an RNA vector for Sickle cell disease: the “all-in-one” vector
Project Number1R21EB034346-01A1
Former Number1R21EB034346-01
Contact PI/Project LeaderDEVAUX, PATRICIA
Awardee OrganizationMAYO CLINIC ROCHESTER
Description
Abstract Text
Abstract.
The choice of a delivery system for genetic manipulation or gene expression remains a topic of debate in the
research community. The development of a safe, unique, and efficient delivery vehicle that could promote gene
editing would significantly contribute to the field of gene therapy and regenerative medicine. Recently, we have
demonstrated that the Measles virus can be developed as a single cycle vector for multiple gene delivery. We
have shown that we can express the four reprogramming factors from on single measles genome and reprogram
adult human fibroblasts into induced pluripotent stem cells. We further have evidence that MeV can express the
gene-editing system CRISPR-Cas9 and lead to the correction of cells in the presence of a molecule of DNA
template. The goal of this application is to develop new prototype measles vectors that can either genetically
modify or correct a specific gene locus without relying on a DNA molecule using Prime Editors. As a proof of
concept, we will develop prototype vectors based on the vaccine strain of the measles virus, a negative-strand
RNA virus. The objectives of this application are (1) to establish the proof of principle that the MeV vector can
express the Prime Editing system (MeV-PE2). To do this, we will express the two elements required for prime
Editing: the Prime editor (PE2) and prime editor guide RNA (pegRNA), and test their functionality in producing
modified cells for the correction of Sickle cell disease (SCD) (2) In the second aim, we will introduce the latest
generation of Prime editor in MeV vector (MeV-PEmax), which consists of the PE2 and the introduction of (i) a
standard gRNA targeting the non-edited template, (ii) the MLH1dn protein to reduce mismatch repair or (iii) a
modified pegRNA to increase its stability. The proposed work is innovative, challenging, and significant, and if
successful, it will lead to the production of novel prototypes of “all-in-one” non-integrating RNA viral vectors for
cellular gene editing without the addition of an exogenous molecule of DNA. This work will open the future
development of safe vectors for gene editing and the production of corrected cells for multiple genetic disorders.
This new platform will have a significant impact in the field of gene therapy and regenerative medicine.
Public Health Relevance Statement
Narrative
The proposed research will have a high impact in the field of medicine, as it will develop new prototype vectors
able to deliver the Prime Editor system efficiently, leading to the production of safer modified cells. In addition,
this research is relevant to public health, and it will have a meaningful impact on developing new regenerative
medicine and gene therapy approaches to treat monogenic diseases and other genetic diseases.
National Institute of Biomedical Imaging and Bioengineering
CFDA Code
286
DUNS Number
006471700
UEI
Y2K4F9RPRRG7
Project Start Date
01-June-2024
Project End Date
30-April-2026
Budget Start Date
01-June-2024
Budget End Date
30-April-2025
Project Funding Information for 2024
Total Funding
$217,890
Direct Costs
$135,000
Indirect Costs
$82,890
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Biomedical Imaging and Bioengineering
$217,890
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R21EB034346-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R21EB034346-01A1
Patents
No Patents information available for 1R21EB034346-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R21EB034346-01A1
Clinical Studies
No Clinical Studies information available for 1R21EB034346-01A1
News and More
Related News Releases
No news release information available for 1R21EB034346-01A1
History
No Historical information available for 1R21EB034346-01A1
Similar Projects
No Similar Projects information available for 1R21EB034346-01A1